What happened this week in #LungCancer:

1️⃣ Resistance-Informed Sequencing in EGFR mNSCLC

In 1L EGFR-mutant NSCLC, treatment decisions are increasingly guided by known resistance patterns. Studies comparing tumor samples before treatment and after disease progression have identified common acquired alterations, including MET amplification, CDKN2A/B deletion, MTAP loss, and the EGFR C797S mutation. These findings highlight the importance of anticipating both on-target resistance and bypass pathway activation when planning therapy sequencing.
aacrjournals.org/cancerdiscover… 2️⃣ TTF-1 negativity in Lung Adenocarcinoma

TTF-1 negativity in lung adenocarcinoma defines a distinct high-risk subset with consistently poorer outcomes and lower responses across ICI, chemo-IO and KRASG12C inhibitor strategies. Supporting TTF-1 negativity may identify a high-risk subset as a pragmatic stratifier for expectations, trial design and evidence-generation in routine advanced LUAD care.
jto.org/article/S1556-…